DNA Repair Therapy for Neurodegeneration

📖 Wiki Page

therapeutic869 wordssynced 2026-04-02

DNA Repair Therapy for Neurodegeneration

Introduction

Dna Repair Therapy For Neurodegeneration is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

Overview

DNA repair therapy aims to counteract the accumulation of DNA damage that occurs with aging and is accelerated in neurodegenerative diseases. This approach includes enhancing base excision repair, nucleotide excision repair, and other DNA repair pathways to protect neuronal genomes and maintain cellular function. [@jeppesen2011]
'''DNA Repair Therapy for Neurodegenerative Diseases''' addresses the accumulating DNA damage that occurs in aging neurons and is accelerated in neurodegenerative conditions. This page covers the role of DNA damage in neurodegeneration, therapeutic strategies to enhance DNA repair, and clinical applications. [@rass2007]

{| class="infobox" [@hoeijmakers2009]
|- [@bedoyan2012]
! colspan="2" style="background:#e8f4ea;font-size:120%;" | DNA Repair Therapy
|-
| '''Category''' || Therapeutic Intervention
|-
| '''Target Conditions''' || AD, PD, ALS, HD, Ataxias, Stroke
|-
| '''Mechanism''' || Enhance DNA repair pathways
|-
| '''Delivery Routes''' || Oral, IV, Gene therapy
|-
| '''Clinical Stage''' || Preclinical to Phase II
|-
| '''Key Targets''' || PARP, BER, NER, HR
|}

== Overview ==

...

DNA Repair Therapy for Neurodegeneration

Introduction

Overview

== Overview ==

[Neurons](/entities/neurons) are post-mitotic cells that cannot divide, making them unable to replicate their DNA. Over a lifetime, neurons accumulate oxidative DNA damage, single-strand breaks, and double-strand breaks. In neurodegenerative diseases, this damage accumulates faster due to increased oxidative stress, mitochondrial dysfunction, and impaired repair mechanisms.

== DNA Repair Pathways in the Brain ==

=== Base Excision Repair (BER) ===

Repairs small, non-helix-distorting lesions
Key enzymes: OGG1, NTH1, PARP1, Pol β
Critical for removing 8-oxoguanine

Nucleotide Excision Repair (NER) ###

Removes bulky DNA adducts
XPA-XPG proteins in transcription-coupled NER
Defects cause ataxia-telangiectasia

=== Mitochondrial DNA Repair ###

Limited BER in mitochondria
Mitochondrial-targeted enzymes

=== Double-Strand Break Repair ===

Homologous recombination (HR)
Non-homologous end joining (NHEJ)
Critical for neuronal survival

== Therapeutic Strategies ==

=== PARP Inhibitors ===

'''Olaparib, rucaparib, niraparib*: Approved for cancer

Prevent excessive PARP activation that depletes NAD+
Neuroprotective in preclinical models
Currently in trials for ALS and PD

=== DNA Glycosylase Enhancers ===

Enhance OGG1 activity to remove 8-oxoguanine
Small molecule activators in development

=== Polynucleotide Kinase Phosphatase (PNKP) Modulators ===

Enhance repair of oxidative DNA damage
Relevant for neurological disorders

=== Gene Therapy Approaches ===

Deliver DNA repair genes to neurons
AAV-PARP1, AAV-OGG1 in development

=== Antioxidant-Dependent Protection ===

Reduce DNA damage at source
Synergistic with direct repair enhancement

== Disease-Specific Applications ==

=== Alzheimer's Disease ===

Accumulation of 8-oxoguanine in brain
PARP1 overactivation depletes NAD+
[Aβ](/proteins/amyloid-beta) induces DNA damage response
PARP inhibitors show promise in models

=== Parkinson's Disease ===

Mitochondrial DNA mutations accumulate
Complex I deficiency increases [ROS](/entities/reactive-oxygen-species)
8-oxoguanine in substantia nigra neurons
PARP1 implicated in dopaminergic death

=== Amyotrophic Lateral Sclerosis (ALS) ===

[TDP-43](/proteins/tdp-43) pathology impairs DNA repair
FUS mutations disrupt DNA damage response
Oxidative DNA damage accelerates disease
PARP inhibitors in clinical trials

=== Huntington's Disease ===

Mutant [huntingtin](/proteins/huntingtin-protein) impairs BER
DNA damage accumulates in striatum
Transglutaminase crosslinks DNA
Poly(ADP-ribose) glycohydrolase inhibitors in development

=== Ataxia-Telangiectasia ===

ATM kinase deficiency causes neurodegeneration
Gene therapy approaches in trials

=== Stroke ===

Ischemia causes massive DNA damage
PARP activation contributes to cell death
PARP inhibitors protective in stroke models

== Clinical Trial Status ==

{| class="wikitable"
|-
! Agent
! Condition
! Phase
! Status
! Trial ID
|-
| PJ34
| ALS
| Preclinical
| Ongoing
| —
|-
| Olaparib
| PD
| Phase I
| Recruiting
| NCT03980908
|-
| EPI-743
| ALS/PD
| Phase II
| Completed
| NCT01962346
|-
| Ribavirin
| Ataxia
| Phase II
| Completed
| NCT01814469
|}

== Challenges and Limitations ==

[BBB](/entities/blood-brain-barrier) penetration: Many agents poorly cross
Cancer risk: DNA repair inhibition may increase tumorigenesis
Specificity: Targeting neurons specifically is difficult
Therapeutic window: Balancing repair enhancement vs. inhibition
Biomarkers: Need better DNA damage markers

== Combination Approaches ==

PARP inhibitors + NAD+ precursors
Antioxidants + DNA repair enhancers
Gene therapy + small molecules

== Future Directions ===

Targeted delivery to neurons using peptide conjugates
Combination therapies addressing multiple pathways
Biomarker-guided patient selection
Gene therapy with viral vectors

== See Also ==

[DNA Damage Response Pathway](/mechanisms/dna-damage-response-pathway)
[Oxidative Stress Pathway](/mechanisms/oxidative-stress-pathway)
[PARP Inhibitors](/therapeutics/parp-inhibitors-neurodegeneration)
[NAD+ Boosters](/therapeutics/nad-boosters-neurodegeneration)
[Mitochondrial Dysfunction Pathway](/mechanisms/mitochondrial-dysfunction-pathway)

== References ==

Katyal S, et al. (2014). "DNA damage repair in neurodegenerative disease." ''Cell''. PMID: 25532893(https://pubmed.ncbi.nlm.nih.gov/25532893/)

Hegde ML, et al. (2015). "Neuronal DNA damage response: An emerging player in neurodegeneration." ''Molecular Neurobiology''. PMID: 25726865(https://pubmed.ncbi.nlm.nih.gov/25726865/)

Poirier Y, et al. (2020). "Therapeutic targeting of PARP in neurodegenerative diseases." ''Expert Opinion on Therapeutic Targets''. PMID: 32741234(https://pubmed.ncbi.nlm.nih.gov/32741234/)

Coppedè F, Migliore L. (2015). "DNA damage in neurodegenerative diseases." ''Mutation Research''. PMID: 25727014(https://pubmed.ncbi.nlm.nih.gov/25727014/)

Miller C, et al. (2020). "DNA repair as a therapeutic target in neurodegenerative disease." ''Free Radical Biology and Medicine''. PMID: 31981565(https://pubmed.ncbi.nlm.nih.gov/31981565/)

Background

The study of Dna Repair Therapy For Neurodegeneration has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

Pathway Diagram

The following diagram shows key molecular relationships for DNA Repair Therapy for Neurodegeneration based on knowledge graph edges:

Mermaid diagram (expand to render)

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

[Nutrient-Sensing Epigenetic Circuit Reactivation](/hypothesis/h-4bb7fd8c) — 0.79 · Target: SIRT1
[CYP46A1 Overexpression Gene Therapy](/hypothesis/h-2600483e) — 0.79 · Target: CYP46A1
[Circadian Glymphatic Entrainment via Targeted Orexin Receptor Modulation](/hypothesis/h-9e9fee95) — 0.77 · Target: HCRTR1/HCRTR2
[Selective Acid Sphingomyelinase Modulation Therapy](/hypothesis/h-de0d4364) — 0.77 · Target: SMPD1
[Membrane Cholesterol Gradient Modulators](/hypothesis/h-9d29bfe5) — 0.76 · Target: ABCA1/LDLR/SREBF2
[Microbial Inflammasome Priming Prevention](/hypothesis/h-e7e1f943) — 0.76 · Target: NLRP3, CASP1, IL1B, PYCARD
[Blood-Brain Barrier SPM Shuttle System](/hypothesis/h-959a4677) — 0.75 · Target: TFRC
[Purinergic Signaling Polarization Control](/hypothesis/h-0758b337) — 0.74 · Target: P2RY1 and P2RX7

Related Analyses:

[Synaptic pruning by microglia in early AD](/analysis/SDA-2026-04-01-gap-v2-691b42f1) 🔄
[SEA-AD Gene Expression Profiling — Allen Brain Cell Atlas](/analysis/analysis-SEAAD-20260402) 🔄
[APOE4 structural biology and therapeutic targeting strategies](/analysis/SDA-2026-04-01-gap-010) 🔄
[Senescent cell clearance as neurodegeneration therapy](/analysis/SDA-2026-04-02-gap-senescent-clearance-neuro) 🔄
[4R-tau strain-specific spreading patterns in PSP vs CBD](/analysis/SDA-2026-04-01-gap-005) 🔄

Pathway Diagram

The following diagram shows the key molecular relationships involving DNA Repair Therapy for Neurodegeneration discovered through SciDEX knowledge graph analysis:

Mermaid diagram (expand to render)

📖 View canonical wiki page →

DNA Repair Therapy for Neurodegeneration

DNA Repair Therapy for Neurodegeneration

Introduction

Overview

DNA Repair Therapy for Neurodegeneration

Introduction

Overview

Nucleotide Excision Repair (NER) ###

Background

See Also

Pathway Diagram

Related Hypotheses

Pathway Diagram